Want to see SE:PAX full AI Analyst Report?
PAX Stock Chart & Stats
kr46.75
kr0.40(0.86%)
At close: 4:00 PM EDT
kr46.75
kr0.40(0.86%)
Day’s Range― - ―
52-Week Rangekr41.00 - kr80.80
Previous CloseN/A
Volume1.85K
Average Volume (3M)100.37K
Market Cap
kr1.06B
Enterprise Valuekr1.02K
Total Cash (Recent Filing)kr106.09M
Total Debt (Recent Filing)kr4.58M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Aug 21, 2026EPS Estimate
0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding23,273,417
10 Day Avg. Volume41,338
30 Day Avg. Volume100,373
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)3.05
Price to Sales (P/S)3.95
P/FCF Ratio-76.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.86
Revenue Forecast (FY)kr412.65M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And DemandSustained sales expansion and a substantial order book indicate growing adoption of scalp cooling across oncology providers. This supports future equipment revenue while expanding the installed base that can generate recurring consumables and service income.
Higher Recurring UtilizationInsurance-based billing improves patient access and materially increases system utilization, supporting recurring cap revenue and better economics per installed system. Wider adoption could make revenue less dependent on one-time equipment placements.
Conservative Balance SheetVery low leverage gives Paxman financial flexibility to fund international expansion, product development and integration without relying heavily on debt. This reduces balance-sheet risk while the company works toward more consistent profitability and cash generation.
Bears Say
Recent Losses And Weak Cash GenerationThe shift from prior profits to net losses, combined with negative operating and free cash flow, raises execution risk if investment and working-capital needs remain elevated. Persistent losses could eventually reduce funding flexibility despite low leverage.
Neuropathy Device Regulatory DelayThe De Novo pathway delays potential U.S. revenue from the neuropathy device and creates uncertainty over additional evidence requirements. A longer approval process also extends development spending before the product can contribute commercially.
Higher Development And Operating CostsHigher CIPN, regulatory, research and commercialization spending is reducing reported margins while the new product remains unapproved. If these costs persist alongside the delayed launch, near-term earnings and cash conversion may remain pressured.
Paxman AB News
PAX FAQ
What was Paxman AB’s price range in the past 12 months?
Paxman AB lowest stock price was kr41.00 and its highest was kr80.80 in the past 12 months.
What is Paxman AB’s market cap?
Paxman AB’s market cap is kr1.06B.
When is Paxman AB’s upcoming earnings report date?
Paxman AB’s upcoming earnings report date is Aug 21, 2026 which is yesterday.
How were Paxman AB’s earnings last quarter?
Currently, no data Available
Is Paxman AB overvalued?
According to Wall Street analysts Paxman AB’s price is currently Overvalued.
Does Paxman AB pay dividends?
Paxman AB does not currently pay dividends.
What is Paxman AB’s EPS estimate?
Paxman AB’s EPS estimate is 0.3.
How many shares outstanding does Paxman AB have?
Paxman AB has 23,273,417 shares outstanding.
What happened to Paxman AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Paxman AB?
Currently, no hedge funds are holding shares in SE:PAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Paxman AB
Paxman AB (publ), along with its subsidiaries, specializes in the creation and worldwide sale of the Paxman scalp cooling system, an innovative solution designed to minimize hair loss in patients undergoing chemotherapy. This system is distributed across Europe, the United States, Mexico, Japan, Oceania, various Asian regions, and both South and Central America, primarily serving cancer centers and hospitals. The company is also engaged in a research collaboration agreement with the National University Hospital in Singapore, working towards the development of a portable cooling and compression device. Established in 1996, Paxman AB (publ) is headquartered in Karlshamn, Sweden.
PAX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong commercial momentum: record quarterly sales (+40% YoY), substantial U.S. revenue growth (~+77.5% YoY), large increases in insurance-based billing (110%), improved adjusted margins (~19%), a robust order book (190 systems, 80 in U.S.), and a healthy cash position (SEK 105m). These positives are tempered by a regulatory setback for the neuropathy device (shift to De Novo with an 8–12 month review window), increased operating and CIPN-related costs (OpEx up ~SEK 6m q/q; CIPN costs up ~30%), and a slower near-term U.S. rollout for CIPN. Overall, company fundamentals and commercial traction are strong and appear to outweigh the regulatory and cost challenges, but the De Novo timeline introduces meaningful near-term uncertainty for the new product launch.View all SE:PAX earnings summariesTechnical Analysis
Senzime AB
―
Xvivo Perfusion AB
―
Bactiguard Holding AB
―
BrainCool AB
―
Sedana Medical AB
―